35883437|t|A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions.
35883437|a|Dopamine (DA), the most abundant human brain catecholaminergic neurotransmitter, modulates key behavioral and neurological processes in young and senescent brains, including motricity, sleep, attention, emotion, learning and memory, and social and reward-seeking behaviors. The DA transporter (DAT) regulates transsynaptic DA levels, influencing all these processes. Compounds targeting DAT (e.g., cocaine and amphetamines) were historically used to shape mood and cognition, but these substances typically lead to severe negative side effects (tolerance, abuse, addiction, and dependence). DA/DAT signaling dysfunctions are associated with neuropsychiatric and progressive brain disorders, including Parkinson's and Alzheimer diseases, drug addiction and dementia, resulting in devastating personal and familial concerns and high socioeconomic costs worldwide. The development of low-side-effect, new/selective medicaments with reduced abuse-liability and which ameliorate DA/DAT-related dysfunctions is therefore crucial in the fields of medicine and healthcare. Using the rat as experimental animal model, the present work describes the synthesis and pharmacological profile of (S)-MK-26, a new modafinil analogue with markedly improved potency and selectivity for DAT over parent drug. Ex vivo electrophysiology revealed significantly augmented hippocampal long-term synaptic potentiation upon acute, intraperitoneally delivered (S)-MK-26 treatment, whereas in vivo experiments in the hole-board test showed only lesser effects on reference memory performance in aged rats. However, in effort-related FR5/chow and PROG/chow feeding choice experiments, (S)-MK-26 treatment reversed the depression-like behavior induced by the dopamine-depleting drug tetrabenazine (TBZ) and increased the selection of high-effort alternatives. Moreover, in in vivo microdialysis experiments, (S)-MK-26 significantly increased extracellular DA levels in the prefrontal cortex and in nucleus accumbens core and shell. These studies highlight (S)-MK-26 as a potent enhancer of transsynaptic DA and promoter of synaptic plasticity, with predominant beneficial effects on effort-related behaviors, thus proposing therapeutic potentials for (S)-MK-26 in the treatment of low-effort exertion and motivational dysfunctions characteristic of depression and aging-related disorders.
35883437	54	63	(S)-MK-26	Chemical	-
35883437	134	159	Motivational Dysfunctions	Disease	MESH:D006331
35883437	161	169	Dopamine	Chemical	MESH:D004298
35883437	171	173	DA	Chemical	MESH:D004298
35883437	194	199	human	Species	9606
35883437	439	453	DA transporter	Gene	6531
35883437	455	458	DAT	Gene	6531
35883437	484	486	DA	Chemical	MESH:D004298
35883437	548	551	DAT	Gene	6531
35883437	559	566	cocaine	Chemical	MESH:D003042
35883437	571	583	amphetamines	Chemical	MESH:D000662
35883437	724	733	addiction	Disease	MESH:D019966
35883437	752	754	DA	Chemical	MESH:D004298
35883437	755	758	DAT	Gene	24898
35883437	802	850	neuropsychiatric and progressive brain disorders	Disease	MESH:D001927
35883437	862	896	Parkinson's and Alzheimer diseases	Disease	MESH:D010300
35883437	898	912	drug addiction	Disease	MESH:D019966
35883437	917	925	dementia	Disease	MESH:D003704
35883437	1135	1137	DA	Chemical	MESH:D004298
35883437	1138	1141	DAT	Gene	24898
35883437	1236	1239	rat	Species	10116
35883437	1342	1351	(S)-MK-26	Chemical	-
35883437	1359	1368	modafinil	Chemical	MESH:D000077408
35883437	1429	1432	DAT	Gene	24898
35883437	1594	1603	(S)-MK-26	Chemical	-
35883437	1733	1737	rats	Species	10116
35883437	1779	1783	PROG	Chemical	-
35883437	1817	1826	(S)-MK-26	Chemical	-
35883437	1850	1860	depression	Disease	MESH:D003866
35883437	1890	1898	dopamine	Chemical	MESH:D004298
35883437	1914	1927	tetrabenazine	Chemical	MESH:D013747
35883437	1929	1932	TBZ	Chemical	MESH:D013747
35883437	2039	2048	(S)-MK-26	Chemical	-
35883437	2087	2089	DA	Chemical	MESH:D004298
35883437	2187	2196	(S)-MK-26	Chemical	-
35883437	2235	2237	DA	Chemical	MESH:D004298
35883437	2382	2391	(S)-MK-26	Chemical	-
35883437	2436	2461	motivational dysfunctions	Disease	MESH:D006331
35883437	2480	2490	depression	Disease	MESH:D003866
35883437	2495	2518	aging-related disorders	Disease	MESH:D008569
35883437	Positive_Correlation	MESH:D000662	MESH:D019966
35883437	Negative_Correlation	MESH:D004298	MESH:D013747
35883437	Positive_Correlation	MESH:D013747	MESH:D003866
35883437	Negative_Correlation	MESH:D000077408	24898
35883437	Association	MESH:D004298	MESH:D003704
35883437	Association	MESH:D004298	MESH:D010300
35883437	Association	MESH:D004298	24898
35883437	Association	MESH:D004298	MESH:D019966
35883437	Association	MESH:D003704	24898
35883437	Association	MESH:D010300	24898
35883437	Association	MESH:D003704	6531
35883437	Association	MESH:D000662	6531
35883437	Association	MESH:D019966	6531
35883437	Association	MESH:D004298	MESH:D001927
35883437	Negative_Correlation	MESH:D003042	6531
35883437	Association	MESH:D019966	24898
35883437	Negative_Correlation	MESH:D004298	MESH:D003866
35883437	Association	MESH:D001927	24898
35883437	Positive_Correlation	MESH:D003042	MESH:D019966
35883437	Association	MESH:D004298	6531

